Our objective is to analyze the economic burden of chronic kidney disease (CKD) in Vietnam, particularly in District 2 Hospital at Ho Chi Minh City in 2019. This is a descriptive cross-sectional study. The data source is the medical records of the patients. Encoding the data, analyzing treatment cost, regression modeling, and verification were performed using Stata 15 software. Patients with stage 3 CKD account for the highest proportion of the CKD patient population. CKD comorbidities include hypertension, diabetes, cardiovascular disease, and anemia, which increase the treatment fees of patients. Approximately half of the patients with CKD have diabetes or cardiovascular disease. Treatment costs increase as the condition of the patient worsens (except for stage 1 and 2 CKD). The total expenses of all CKD patients in District 2 Hospital were USD 916 423 988.60. Five main factors that affect the treatment fee of a patient: CKD stage, age, gender, and the presence of diabetes, cardiovascular disease, and anemia. The regression model correctly predicts 96% of cases and can explain 64.15% of the fluctuations in costs. The cost of CKD treatment was higher than Vietnam’s per capita GDP in 2019, and the primary factors affecting costs are comorbidities and dialysis.

1. Couser, WG, Remuzzi, G, Mendis, S, Tonelli, M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258-1270.
Google Scholar | Crossref | Medline | ISI2. Saran, R, Li, Y, Robinson, B, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(suppl 1): Svii, S1-305.
Google Scholar | Crossref3. Honeycutt, AA, Segel, JE, Zhuo, X, Hoerger, TJ, Imai, K, Williams, D. Medical costs of CKD in the medicare population. J Am Soc Nephrol. 2013;24:1478-1483.
Google Scholar | Crossref | Medline4. Brück, K, Stel, VS, Gambaro, G, et al. CKD prevalence varies across the European General Population. J Am Soc Nephrol. 2016;27:2135-2147.
Google Scholar | Crossref | Medline | ISI5. Turchetti, G, Bellelli, S, Amato, M, et al. The social cost of chronic kidney disease in Italy. Eur J Health Econ. 2017;18:847-858.
Google Scholar | Crossref | Medline6. Songsermlosakul, S, Permsuwan, U, Singhan, W. Treatment costs for patients with chronic kidney disease who received multidisciplinary care in a district hospital in thailand. Clinicoecon Outcomes Res. 2020;12:223-231.
Google Scholar | Crossref | Medline7. Zhang, L, Li, Z. Chronic Kidney Disease in China. Elsevier Inc.; 2017.
Google Scholar | Crossref8. Manning, WG, Mullahy, J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494.
Google Scholar | Crossref | Medline | ISI9. Baumeister, SE, Böger, A, Krämer, BK, et al. Effect of chronic kidney disease and comorbid conditions on health care costs: a 10-year observational study in a general population. Am J Nephrol. 2010;31:222-229.
Google Scholar | Crossref | Medline10. Centers for Disease Control and Prevention (CDC) . Prevalence of chronic kidney disease and associated risk factors—United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161-165.
Google Scholar | Medline11. Turner, JM, Bauer, C, Abramowitz, MK, Melamed, ML, Hostetter, TH. Treatment of chronic kidney disease. Kidney Int. 2012;81:351-362.
Google Scholar | Crossref | Medline | ISI12. Golestaneh, L, Alvarez, PJ, Reaven, NL, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23:S163-S172.
Google Scholar | Medline13. Vupputuri, S, Kimes, TM, Calloway, MO, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications. 2014; 28:10-16.
Google Scholar | Crossref | Medline14. Ozieh, MN, Dismuke, CE, Lynch, CP, Egede, LE. Medical care expenditures associated with chronic kidney disease in adults with diabetes: United States 2011. Diabetes Res Clin Pract. 2015;109:185-190.
Google Scholar | Crossref | Medline